Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 773-780

  Somers, Kenneth D ^a   Brown, Roy R ^a   Holterman, Daniel A ^a   Yousefieh, Nazita ^a   Glass, William F ^a   Wright Jr , George L ^a,b   Schellhammer, Paul F ^a,b   Qian, Jesse ^a   Ciavarra, Richard P ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Network   (United States)

Author keywords

Flt3 ligand; Immunotherapy; Metastasis; Orthotopic mouse model; Prostate cancer

Indexed keywords

FLT3 LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; GENE AMPLIFICATION; IMMUNOCOMPETENCE; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PARAAORTIC LYMPH NODE; PLOIDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; TRANSGENE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PLOIDIES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; TUMOR CELLS, CULTURED;

EID: 0242332099     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11464     Document Type: Article

References (26)

1. Kuku H, Lee WR, Bare R, Hall MC, Torti FM. Recent advances in the treatment of prostate cancer. Ann Oncol 1999;10:891-8.
2. Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000;92:1717-30.
3. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000;43:263-71.
4. Stephenson RA, Dinney CPN, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992;84:951-7.
5. Fu X, Herrera H, Hoffman RM. Orthotopic growth and metastasis of human prostate carcinoma in nude mice after transplantation of histologically intact tissue. Int J Cancer 1992;52:987-90.
6. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
7. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
8. Greene JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998;36:59-63.
9. Thompson TC, Timme TL, Park SH, Yang G, Ren C. Mouse prostate reconstitution model system: a series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 2000;43:248-54.
10. Greenberg NM, DeMayo FJ, Feingold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-43.
11. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998;78:319-33.
12. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
13. Ciavarra RP, Somers KD, Brown RR, Glass WF, deAngelis Consolvo PJ, Wright GL, Schellhammer PF. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 2000;60:2081-4.
14. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-30.
15. Krill D, Shuman M, Thompson MT, Becich MJ, Strom SC. A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 1997;49:981-8.
16. Jacobs SC. Spread of cancer to bone. Urology 1983;21:337-44.
17. Garabedian EM, Humphrey PA, Gordon JL. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95:15382-7.
18. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61:2239-49.
19. Nemeth JA, Harb JF, Barroso U, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-93.
20. Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/ severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 2001;61:2177-82.
21. Antonysamy MA, Thomson AW. Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 2000;12:87-100.
22. Dong J, McPherson CM, Stambrook PJ. Flt3 ligand: a potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 2002;1:486-9.
23. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-7.
24. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF II, Wright GL, Jr, Schellhammer PF, Somers KD. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 2003;52:535-45.
25. Averbook BJ, Schuh JL, Papay R, Maliszewski C. Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother 2002;25:27-35.
26. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96:1480-9.